Welcome to our dedicated page for Rapport Therapeutics SEC filings (Ticker: RAPP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Rapport Therapeutics, Inc. (Nasdaq: RAPP) provides access to the company’s official regulatory disclosures as a clinical-stage biotechnology issuer. Rapport’s common stock is registered under Section 12(b) of the Securities Exchange Act of 1934 and listed on The Nasdaq Global Market under the symbol RAPP, so its filings offer detailed information on its precision neuroscience business and capital markets activity.
Through this page, readers can review Form 10-K and Form 10-Q reports (when filed) for discussions of Rapport’s RAP technology platform, the development of RAP-219 for drug-resistant focal onset seizures, bipolar mania, and diabetic peripheral neuropathic pain, and additional programs in chronic pain, migraine, and hearing or vestibular disorders. These periodic reports also describe risk factors, research and development expenses, and other elements of the company’s operating profile.
Frequent Form 8-K filings from RAPP document material events such as positive Phase 2a trial results for RAP-219 in focal onset seizures, new data analyses presented at scientific meetings, public offerings of common stock under an effective shelf registration statement on Form S-3, and quarterly financial results and business updates. Some 8-Ks also summarize regulatory developments, including clinical holds, end-of-Phase 2 planning, and changes to at-the-market sales arrangements.
Investors can also use this page to locate information related to shareholder meetings and voting outcomes, as disclosed in 8-K items covering submissions of matters to a vote of security holders. Insider transaction reports on Form 4, when available, complement these filings by showing equity activity by directors and officers.
Stock Titan enhances these documents with AI-powered summaries that explain key points from lengthy filings, highlight clinical and financial milestones, and make it easier to understand how new disclosures may relate to Rapport’s RAP-219 program and broader precision neuroscience pipeline. Real-time updates from EDGAR help ensure that new RAPP filings, including 10-K, 10-Q, 8-K, and Form 4 submissions, are quickly accessible in one place.
Rapport Therapeutics reported that Chief Medical Officer Jeffrey Sevigny received a grant of stock options on February 2, 2026. The award covers 130,000 stock options to purchase common stock at an exercise price of $27.75 per share, expiring on February 2, 2036.
The options vest in 48 equal monthly installments starting after January 1, 2026, and require Dr. Sevigny’s continued service on each vesting date. After this grant, he beneficially owns 130,000 derivative securities directly.
Rapport Therapeutics CEO Abraham Ceesay received a new stock option grant covering 428,000 shares of common stock. The option has an exercise price of $27.75 per share and was awarded on February 2, 2026. It was reported as a direct holding.
The shares underlying this option vest in forty-eight equal monthly installments following January 1, 2026, conditioned on Ceesay’s continued service with the company on each vesting date. After this grant, he beneficially owned 428,000 derivative securities in the form of stock options.
Rapport Therapeutics reported that its Chief Financial Officer, Troy Ignelzi, received a new stock option award. On February 2, 2026, he was granted an option to buy 148,000 shares of common stock at an exercise price of $27.75 per share. The option vests in 48 equal monthly installments following January 1, 2026, as long as he continues in service on each vesting date, and is scheduled to expire on February 2, 2036. After this grant, he directly beneficially owns 148,000 derivative securities in the form of this option.
Rapport Therapeutics reported that Chief Development Officer Yeleswaram Krishnaswamy received a stock option award. The option gives the right to buy 120,000 shares of common stock at an exercise price of $27.75 per share and expires on February 2, 2036.
The option was granted on February 2, 2026 and vests in 48 equal monthly installments following January 1, 2026, as long as Krishnaswamy continues in service on each vesting date. After this grant, he beneficially owns options for 120,000 shares, held directly.
Rapport Therapeutics Chief Scientific Officer granted 103,000 stock options. The Form 4 shows that officer David Bredt received a stock option covering 103,000 shares of common stock at an exercise price of $27.75 per share on February 2, 2026.
The option vests in forty-eight equal monthly installments following January 1, 2026, contingent on his continued service with the company on each vesting date. The option is scheduled to expire on February 2, 2036 if not exercised.
Rapport Therapeutics, Inc. reported that Chief Operating Officer Cheryl Gault received a stock option grant for 132,000 shares of common stock on February 2, 2026, with an exercise price of $27.75 per share and expiration on February 2, 2036.
The option vests in forty-eight equal monthly installments starting after January 1, 2026, conditioned on her continued service with the company. Following this grant, she beneficially owns 132,000 derivative securities directly.
Rapport Therapeutics Chief Executive Officer Abraham Ceesay, who is also a director, reported planned sales of company stock. On January 20, 2026, he sold 5,833 shares of common stock directly at a weighted average price of $26.1158, leaving him with 562,080 directly held shares.
On the same date, 5,083 shares of Rapport common stock were sold at a weighted average price of $26.114 by The Dorothy Ceesay Irrevocable Trust, which now holds 25,812 shares, and a separate Ceesay Family Irrevocable Trust holds 81,729 shares. All reported sales were made under Rule 10b5-1 trading plans adopted on December 12, 2024. The trusts are associated with Ceesay, but he disclaims beneficial ownership of their shares except to the extent of any pecuniary interest.
Rapport Therapeutics Inc. disclosed that BlackRock, Inc. has become a significant institutional holder of its common stock. BlackRock reports beneficial ownership of 2,397,549 shares of Rapport common stock, representing 5.03% of the outstanding class as of the reporting date.
BlackRock has sole voting power over 2,355,378 shares and sole dispositive power over 2,397,549 shares, with no shared voting or dispositive authority. The filing explains that these holdings are attributed to specific BlackRock business units and that various underlying clients have rights to dividends or sale proceeds, but no single client holds more than five percent of Rapport’s outstanding shares. BlackRock certifies that the position was acquired in the ordinary course of business and not for the purpose of changing or influencing control of Rapport.
Rapport Therapeutics Chief Scientific Officer David Bredt reported selling common stock in the company. On January 15, 2026, he sold 8,300 shares of common stock at a weighted average price of $26.8255 and an additional 200 shares at $27.40. The weighted average sale was executed in multiple trades at prices ranging from $26.33 to $27.30. After these sales, Bredt beneficially owned 395,575 shares of common stock directly. The filing notes that these transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 12, 2024, which is designed to allow insiders to sell shares according to a preset schedule.
David S. Bredt filed a notice of proposed sale under Rule 144 to sell 17,000 shares of common stock through Morgan Stanley Smith Barney LLC on the NASDAQ exchange. The filing lists an aggregate market value of $466,140.00 for these shares and notes that 47,661,138 shares of the issuer’s common stock are outstanding.
The shares to be sold were acquired as founder shares on 03/09/2023, with 17,000 securities acquired and paid for on the same date. Over the past three months, related sales of common stock by David S. Bredt include 6,567 shares sold on 12/31/2025 for $197,337.69, 8,500 shares sold on 12/15/2025 for $255,130.05, and 8,500 shares sold on 11/17/2025 for $214,090.35, with two of these transactions identified as Rule 10b5-1 sales.
FAQ
What is the current stock price of Rapport Therapeutics (RAPP)?
What is the market cap of Rapport Therapeutics (RAPP)?
